Wire · regulatory
FDA rejects Capricor's Duchenne cell therapy deramiocel, citing data integrity violations in ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 November 2026 · Fusion42 review
The FDA issued a complete response letter rejecting Capricor's cell therapy deramiocel for Duchenne muscular dystrophy due to serious data integrity violations in the Phase 3 HOPE-3 trial, including unauthorized statistical changes and blinding breaches that render the data unreliable.
This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 12 Nov 2026 and 21 Nov 2026.
◆ ◆ The Wire takeaway
You face tighter FDA scrutiny for clinical data integrity in rare disease cell therapies. Prepare to overhaul trial design and compliance to keep your Duchenne or similar therapies relevant.
◆ Coverage
4 sources · first reported 12 Nov 2026 · latest 21 Nov 2026
◆ Related on Wire
◆ Topics